DRI Healthcare Trust (TSE:DHT.UN) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of DRI Healthcare Trust (TSE:DHT.UN) have received an average recommendation of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is C$17.94.

A number of research analysts have commented on DHT.UN shares. CIBC dropped their price objective on shares of DRI Healthcare Trust from C$19.50 to C$18.00 and set an “outperform” rating on the stock in a research note on Thursday, December 12th. Raymond James reduced their price objective on DRI Healthcare Trust from C$23.00 to C$22.00 in a research note on Wednesday, November 13th. Finally, Scotiabank lifted their target price on DRI Healthcare Trust from C$21.00 to C$22.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th.

DRI Healthcare Trust Trading Up 0.7 %

DHT.UN stock opened at C$12.12 on Monday. The company has a fifty day moving average price of C$13.10 and a 200 day moving average price of C$13.11. DRI Healthcare Trust has a 12 month low of C$10.39 and a 12 month high of C$17.43.

DRI Healthcare Trust Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 18th. Shareholders of record on Friday, October 18th were issued a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a yield of 2.81%. The ex-dividend date was Friday, September 27th. DRI Healthcare Trust’s dividend payout ratio is presently -920.00%.

About DRI Healthcare Trust

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.